Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

43.35
-0.9200-2.08%
Volume:449.10K
Turnover:19.84M
Market Cap:2.69B
PE:50.26
High:45.26
Open:44.44
Low:43.20
Close:44.27
Loading ...

Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership

TIPRANKS
·
11 Dec 2024

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Dec 2024

Protagonist Therapeutics: Promising Developments and Positive Outlook Justify Buy Rating

TIPRANKS
·
10 Dec 2024

Protagonist Therapeutics announces data from REVIVE study at ASH

TIPRANKS
·
10 Dec 2024

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

ACCESSWIRE
·
10 Dec 2024

Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target

MT Newswires Live
·
06 Dec 2024

Protagonist Therapeutics Inc : Bmo Initiates Coverage With Outperform Rating; Price Target $62

THOMSON REUTERS
·
06 Dec 2024

Hold Rating Maintained for Protagonist Therapeutics Amid Promising Phase 3 Assets and Limited Financial Upside Due to Licensing Agreements

TIPRANKS
·
06 Dec 2024

Protagonist Therapeutics initiated with a Neutral at Goldman Sachs

TIPRANKS
·
06 Dec 2024

Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities

TIPRANKS
·
05 Dec 2024

Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Simply Wall St.
·
29 Nov 2024

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

ACCESSWIRE
·
22 Nov 2024

Protagonist Therapeutics price target raised to $67 from $51 at BTIG

TIPRANKS
·
22 Nov 2024

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Nov 2024

U.S. RESEARCH ROUNDUP- CPI Card Group, First Solar, Viking Therapeutics

Reuters
·
22 Nov 2024

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

ACCESSWIRE
·
22 Nov 2024

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

ACCESSWIRE
·
19 Nov 2024

TD Cowen Remains a Buy on Protagonist Therapeutics (PTGX)

TIPRANKS
·
19 Nov 2024

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Nov 2024

Protagonist Therapeutics Inc Shares Down 5.9% at $38 in Relatively Light Trading Volume After the Bell Following Update From Phase 3 Study of Plague Psoriasis Treatment

THOMSON REUTERS
·
19 Nov 2024